Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients

BACKGROUND: Switch strategies based on rilpivirine/tenofovir/emtricitabine or on an integrase inhibitor (InSTI) plus tenofovir/emtricitabine have never been compared in randomized clinical trials. The main aim of the study was to investigate the durability of these two switch regimens in virological...

Descripción completa

Detalles Bibliográficos
Autores principales: Gianotti, Nicola, Poli, Andrea, Nozza, Silvia, Galli, Laura, Galizzi, Nadia, Ripa, Marco, Merli, Marco, Carbone, Alessia, Spagnuolo, Vincenzo, Lazzarin, Adriano, Castagna, Antonella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691866/
https://www.ncbi.nlm.nih.gov/pubmed/29145807
http://dx.doi.org/10.1186/s12879-017-2831-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691866/
https://www.ncbi.nlm.nih.gov/pubmed/29145807
http://dx.doi.org/10.1186/s12879-017-2831-9

Ejemplares similares